Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
about
Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancerReview of systemic therapies for locally advanced and metastatic rectal cancerCancer and liver cirrhosis: implications on prognosis and managementGemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic functionA comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI)Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.HCV genotype-specific correlation with serum markers: higher predictability for genotype 4aAssociation of laboratory parameters with viral factors in patients with hepatitis C.Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer.Toxicity of the topoisomerase I inhibitors.Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursElderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1Cancer therapies utilizing the camptothecins: a review of the in vivo literatureSerum Alkaline Phosphatase Level as a Prognostic Tool in Colorectal Cancer: A Study of 105 patientsSafety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer.Should cirrhosis change our attitude towards treating non-hepatic cancer?Etirinotecan pegol: development of a novel conjugated topoisomerase I inhibitor.Drug-induced hepatotoxicity in cancer patients - implication for treatment.The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects.Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.Cetuximab for patients with colon cancer and hepatic metastasis complicated by liver dysfunction and icterus.Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction.Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.Autophagy, apoptosis, vitamin D, and vitamin D receptor in hepatocellular carcinoma associated with hepatitis C virus.Treatment of Elderly Patients with Colorectal Cancer.
P2860
Q26775949-E0E74190-295C-41B8-A626-17A21401D101Q27021105-CD77E027-4593-4BB9-8336-599B6EFD6990Q28068579-463B0F99-B6CE-47EB-BDDF-E831951E3CA1Q33358104-1104A108-1B97-4952-9E67-940454236FBDQ33408632-403D170F-36D0-4D42-A701-9864E331C25DQ33593207-95FB349E-7525-437C-B386-2EFFA9A1B91FQ33877980-17B3710B-799C-420E-B760-DE0C53A9FC7EQ34455658-773ADAFF-25BD-4FB1-B355-772939480F7EQ35068407-BBA69EAF-A056-4293-A626-841CB41C0881Q35158444-2D4E4C81-0638-45D0-BF53-53351B352450Q35680674-AD994ED1-0188-4ABB-AECB-C52FBB903ECCQ36040744-C9B3C65F-96C0-4E19-90A3-C85D252A6575Q36648316-813645F6-8492-4028-84F9-2D6710303A1FQ36695795-4E64251F-1F8D-4458-9321-C52B933E77C3Q36998199-2C35FB63-005B-4627-8E66-5E29B8B8986CQ37069556-67EE7AC4-A1F2-4A4E-AFAC-05D997E76A54Q37340995-D50978D7-D5A9-4D6A-9827-8C142BB0835EQ37639225-8B96298A-18AC-48C3-A865-4D9643D2B3BFQ37732059-A5646B5C-92EF-444B-9694-F5EAD51DE45FQ37958071-CCC38944-FE39-4FBB-B523-A06E735FEBE7Q38180311-88645B63-988E-4AEC-9024-2DA88C47FA2EQ38845891-B1C44335-E9D6-4199-8612-9AA74BB3F415Q38866096-DB95B79D-783B-45C1-AFC7-EC63BC46C799Q41910480-58AD9896-6B34-4BE8-BA56-6650325EE824Q42548893-C870AA19-680D-4502-BB2C-1FA90FE85971Q43248670-62555C0B-1E90-4BF1-B136-1E5D8ECB393AQ45158976-EFF13D92-1DFC-4E7E-BB69-3D93F71913DDQ46985267-88DDA843-1BC2-4439-9A8F-38EE5E69B2D5Q51737218-579EC0CF-0301-4A8A-AC63-29B03ED4EBDDQ55424174-A078DCC4-9FDC-4E4B-BCDD-BEFCE0BD936B
P2860
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Dosage adjustment and pharmaco ...... ents with hepatic dysfunction.
@en
Dosage adjustment and pharmaco ...... ents with hepatic dysfunction.
@nl
type
label
Dosage adjustment and pharmaco ...... ents with hepatic dysfunction.
@en
Dosage adjustment and pharmaco ...... ents with hepatic dysfunction.
@nl
prefLabel
Dosage adjustment and pharmaco ...... ents with hepatic dysfunction.
@en
Dosage adjustment and pharmaco ...... ents with hepatic dysfunction.
@nl
P2093
P50
P356
P1476
Dosage adjustment and pharmaco ...... ents with hepatic dysfunction.
@en
P2093
Christian Jacques
Eric Raymond
Ger-Jan Sanderink
Jean-Pierre Armand
Laurent Vernillet
Michel Ducreux
Michel Gatineau
P304
P356
10.1200/JCO.2002.03.123
P407
P577
2002-11-01T00:00:00Z